Advertisement

Spectrum of activity of azithromycin

  • J. D. Williams
Review

Abstract

In recent years, a number of newer macrolides have been developed. One such antibiotic is azithromycin, which has a 15-membered ring structure and is classed as an azalide. The limitations of erythromycin and the discovery of pathogenic bacteria such asCampylobacter, Legionella andChlamydia species provide incentives to study the usefulness of newer antibiotics of this class. Azithromycin has good activity against staphylococci, streptococci,Moraxella catarrhalis and other rapidly growing pyogenic bacteria. The good activity of azithromycin againstHaemophilus influenzae (MIC90 0.5 mg/l) is particularly important as erythromycin has only marginal activity against this organism. Azithromycin has also been shown to be more potent than the macrolides againstEnterobacteriaceae. In common with erythromycin and tetracycline, the agent has good activity againstLegionella, Chlamydia andCampylobacter. Opportunistic infections involvingToxoplasma gondii andPneumocystis carinii are an increasing problem and azithromycin is particularly interesting in view of its activity against these difficult-to-treat organisms.

Keywords

Internal Medicine Tetracycline Erythromycin Pathogenic Bacterium Azithromycin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Osono T: Studi clinici e farmacologici effettuate in Giappone. Giornale Italiano di Chemotherapia 1982, 29, Supplement: 193–205.Google Scholar
  2. 2.
    Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes P: Comparative in vitro activities of new 14-, 15- and 16-membered macrolides. Antimicrobial Agents and Chemotherapy 1988, 32: 1710–1719.PubMedGoogle Scholar
  3. 3.
    Maskell JP, Sefton AM, Williams JD: Comparative in vitro activity of azithromycin against gram-positive cocci,Haemophilus influenzae and anaerobes. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 19–24.PubMedGoogle Scholar
  4. 4.
    Retsema J, Girard A, Schelkley W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R: Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrobial Agents and Chemotherapy 1987, 31: 1937–1947.Google Scholar
  5. 5.
    Slaney L, Chubb H, Ronald A, Brunham R: In vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin againstNeisseria gonorrhoeae, Haemophilus ducreyi and Chlamydia trachomatis. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 1–5.Google Scholar
  6. 6.
    Neu HC, Chin NX, Saha G, Labthavikul P: Comparative in vitro activity of the new oral macrolide azithromycin. European Journal of Clinical Microbiology and Infectious Diseases 1988, 7: 541–544.Google Scholar
  7. 7.
    Steingrimsson O, Olafsson JH, Thorarinson H, Ryan RW, Johnson RB, Tilton RC: Azithromycin in the treatment of sexually transmitted disease. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 109–114.PubMedGoogle Scholar
  8. 8.
    Foulds G, Shepard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 73–82.Google Scholar
  9. 9.
    Krohn K: Gynaecological tissue levels of azithromycin. European Journal of Clinical Microbiology and Infectious Diseases, 10: 864–868.Google Scholar
  10. 10.
    Aronoff SC, Laurent C, Jacobs MR: In vitro activity of erythromycin, roxithromycin and CP-62,993 against common pediatric pathogens. Journal of Antimicrobial Chemotherapy 1987, 19: 275–276.PubMedGoogle Scholar
  11. 11.
    Dunkin KT, Jones S, Howard AJ: The in vitro activity of CP-62,993 againstHaemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococci. Journal of Antimicrobial Chemotherapy 1988, 21: 405–411.PubMedGoogle Scholar
  12. 12.
    Jones K, Felmingham D, Ridgway G: In vitro activity of azithromycin (CP-62,993), a novel macrolide, against enteric pathogens. Drugs under Experimental and Clinical Research 1988, 14: 613–615.PubMedGoogle Scholar
  13. 13.
    Metchock B: In vitro activity of azithromycin compared with other macrolides and oral antibiotics againstSalmonella typhi. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 29–31.PubMedGoogle Scholar
  14. 14.
    Kitzis MD, Goldstein FW, Miegi M, Acar JF: In vitro activity of azithromycin against various gram-negative bacilli and anaerobic bacteria. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 15–18.Google Scholar
  15. 15.
    Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D: Azithromycin concentrations at the sites of pulmonary infection. European Respiratory Journal 1990, 3: 886–890.PubMedGoogle Scholar
  16. 16.
    Goldstein FW, Emiram MF, Coutrot A, Acar JF: Bacteriostatic and bactericidal activity of azithromycin againstHaemophilus influenzae. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 25–28.Google Scholar
  17. 17.
    Jones BM, Kinghorn GR, Duerden BI: In vitro activity of azithromycin and erythromycin against organisms associated with bacterial vaginosis and chancroid. European Journal of Clinical Microbiology and Infectious Diseases 1988, 7: 551–553.Google Scholar
  18. 18.
    Hardy DJ, Hanson CW, Hensey DM, Beyer JM, Fernandes PB: Susceptibility ofCampylobacter pylori to macrolides and fluoroquinolones. Journal of Antimicrobial Chemotherapy 1988, 22: 631–636.Google Scholar
  19. 19.
    McNulty CA, Dent JC: Susceptibility of clinical isolates ofCampylobacter pylori to twenty-one antimicrobial agents. European Journal of Clinical Microbiology and Infectious Diseases 1988, 7: 566–569.Google Scholar
  20. 20.
    Fitzgeorge RB, Featherstone ASR, Baskerville A: Efficacy of azithromycin in the treatment of guinea pigs infected withLegionella pneumophila by aerosol. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 101–108.PubMedGoogle Scholar
  21. 21.
    Edelstein PH, Edelstein MAC: In vitro activity of azithromycin against clinical isolates ofLegionella species. Antimicrobial Agents and Chemotherapy 1991, 35: 180–181.PubMedGoogle Scholar
  22. 22.
    Gladue RP, Bright GM, Isaacson RE, Newborg MF: In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanisms of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy 1989, 33: 277–282.PubMedGoogle Scholar
  23. 23.
    Fenelon LE, Mumtaz G, Ridgway GL: The in vitro antibiotic susceptibility ofChlamydia pneumoniae. Journal of Antimicrobial Chemotherapy 1990, 26: 763–767.PubMedGoogle Scholar
  24. 24.
    Rylander M, Hallander HO: In vitro comparison of the activity of doxycycline, tetracycline, erythromycin and a new macrolide, CP-62,993 againstMycoplasma pneumoniae, Mycoplasma hominis andUreaplasma urealyticum. Scandinavian Journal of Infectious Diseases 1988, 53, Supplement: 12–17.PubMedGoogle Scholar
  25. 25.
    Chang HR, Pechere JC: In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin (CP-62,993) and A-56268) onToxoplasma gondii. Antimicrobial Agents and Chemotherapy 1988, 32: 524–529.PubMedGoogle Scholar
  26. 26.
    Araujo FG, Guptill DR, Remington JS: Azithromycin, a macrolide antibiotic with potent activity againstToxoplasma gondii. Antimicrobial Agents and Chemotherapy 1988, 32: 755–757.PubMedGoogle Scholar
  27. 27.
    Inderlied CB, Kolonoski PT, Wu M, Young LS: In vitro and in vivo activity of azithromycin (CP-62,993) againstMycobacterium avium complex. Journal of Infectious Diseases 1989, 159: 994–997.PubMedGoogle Scholar
  28. 28.
    Naik S, Ruck R: In vitro activities of several new macrolide antibiotics againstMycobacterium avium complex. Antimicrobial Agents and Chemotherapy 1989, 33: 1614–1616.PubMedGoogle Scholar
  29. 29.
    Praec-Mursic V, Wilske B, Schierz G, Suss E, Gross B: Comparative antimicrobial activity of the new macrolides againstBorrelia burgdorferi. European Journal of Clinical Microbiology and Infectious Diseases 1989, 8: 651–652.Google Scholar
  30. 30.
    Johnson RC, Kodner C, Russell M, Girard D: In vitro and in vivo susceptibility ofBorrelia burgdorferi to azithromycin. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 33–38.Google Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1991

Authors and Affiliations

  • J. D. Williams
    • 1
  1. 1.Department of MicrobiologyThe London Hospital Medical CollegeLondonUK

Personalised recommendations